𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial

✍ Scribed by von Minckwitz, Gunter; Puglisi, Fabio; Cortes, Javier; Vrdoljak, Eduard; Marschner, Norbert; Zielinski, Christoph; Villanueva, Cristian; Romieu, Gilles; Lang, István; Ciruelos, Eva; De Laurentiis, Michele; Veyret, Corinne; de Ducla, Sabine; Freudensprung, Ulrich; Srock, Stefanie; Gligorov, Joseph

Book ID
126763319
Publisher
The Lancet
Year
2014
Tongue
English
Weight
297 KB
Volume
15
Category
Article
ISSN
1470-2045

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

FOLFIRI plus cetuximab versus FOLFIRI pl
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
✍ Heinemann, Volker; von Weikersthal, Ludwig Fischer; Decker, Thomas; Kiani, Alexa 📂 Article 📅 2014 🏛 Lancet Publishing Group 🌐 English ⚖ 289 KB

## Background: Cetuximab and bevacizumab have both been shown to improve outcomes in patients with metastatic colorectal cancer when added to chemotherapy regimens; however, their comparative effectiveness when partnered with first-line fluorouracil, folinic acid, and irinotecan (folfiri) is unknow